Baystreet.ca News Commentary – The global biologics industry is experiencing unprecedented expansion as the market surges ...
The potential approval of Vertex’s IgAN therapy povetacicept in 2026 comes amid launch headwinds for the company’s non-opioid ...
Q3 2025 Earnings Call Transcript November 3, 2025 Vertex, Inc. reports earnings inline with expectations. Reported EPS is ...
TipRanks on MSN
Vertex Reports Strong Q3 2025 Results and Stock Buyback
Vertex, Inc. ( ($VERX) ) has released its Q3 earnings. Here is a breakdown of the information Vertex, Inc. presented to its investors. Vertex, ...
The stock, which is down more than 61% in 2025, sold off after reporting a Q3 EPS beat missing on revenue expectations.
Get insights from Vertex Pharmaceuticals' Q3 2025 earnings call—revenue growth, pipeline milestones, and outlook for ALYFTREK, CASGEVY, and JOURNAVX.
BOSTON (AP) — BOSTON (AP) — Vertex Pharmaceuticals Inc. (VRTX) on Monday reported third-quarter net income of $1.08 billion. On a per-share basis, the Boston-based company said it had profit of $4.20.
Vertex, Inc. shares have plunged over 60% YTD, but valuation is now compelling after a post-earnings dip. Learn more about VERX stock here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback